Articles mentioning Bristol-Myers Squibb Co. (BMY)

Results 11 - 20 of 735 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY

Investing | May 21, 2014

1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation

How breakthrough designation for a new multiple myeloma drug helps three drug companies.

Investing | May 21, 2014

3 Stocks This $72 Billion Hedge Fund Recently Bought

Check out which stocks one of the world's most successful hedge funds recently bought and why.

Investing | May 20, 2014

Is Bristol-Myers Squibb's Dividend Unbeatable?

Big pharma's home to many great dividends, but is Bristol-Myers Squibb's yield the best bet for your money?

Investing | May 20, 2014

What Bristol and Celldex's Team-Up Means for Investors

Cancer research as a team sport.

Investing | May 19, 2014

Should a Soaring Market Cap Worry Repligen Corporation Investors?

A quickly-soaring market valuation is hiding a realistic interpretation of Repligen's P/E ratio after the end of a royalty stream from Bristol-Myers Squibb.

Investing | May 16, 2014

Today's Top Health Care Stocks to Watch: Bristol-Myers Squibb and Kamada Ltd.

Top stories in health care and biotech.

Investing | May 15, 2014

Why the National Bank of Greece, Alliant Techsystems Inc., and Bristol-Myers Squibb Co Are Today's 3

Three leading names take big hits on what turned out to be a horrid day for investors, as Bristol-Myers, National Bank of Greece, and Alliant Techsystems all fall in big ways

Investing | May 15, 2014

Could Bristol-Myers End Up Acquiring Celldex?

Celldex (CLDX) began as a subidiary of Bristol-Myers (BMY) Medarex. Here's what you need to know about their collaboration.

Investing | May 14, 2014

Why Celldex Therapeutics Inc. Shares Skyrocketed

Celldex shares soar after it buddies up with this Big Pharma to explore various cancer treatment options in phase 1/2 studies.

Investing | May 13, 2014

ASCO Abstracts: Bristol-Myers Squibb's and Merck's Immuno-Oncology Drugs

Bristol-Myers Squibb's nivolumab and Merck's MK-3475 take center stage for the second year running.

Results 11 - 20 of 735 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY